B R Krause
Affiliation: Pfizer Global Research and Development
- Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosisB R Krause
Department of Cardiovascular Therapeutics, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA
Curr Opin Investig Drugs 2:375-81. 2001..Despite the complexities and uncertainties, drugs should be developed which impact all of the above steps, and short-term endpoints need to be defined for a cautious, systematic approach to clinical evaluation...
- Lipid-lowering effects of WAY-121,898, an inhibitor of pancreatic cholesteryl ester hydrolaseB R Krause
Department of Vascular and Cardiac Diseases, Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, Michigan 48105, USA
Lipids 33:489-98. 1998....
- High correlation but lack of agreement between direct high-performance gel chromatography analysis and conventional indirect methods for determining lipoprotein cholesterolB R Krause
Cardiac and Vascular Diseases, Parke Davis Pharmaceutical Research Div, Warner Lambert Co, Ann Arbor, MI 48105, USA
Clin Chem 42:1996-2001. 1996..In addition, both Bland-Altman plots and concordance correlation analyses indicated lack of agreement between the methods' results in the majority of patients' subgroups...
- Tissue specific changes in acyl-CoA: cholesterol acyltransferase (ACAT) mRNA levels in rabbitsM E Pape
Division of Therapeutics, Parke Davis Pharmaceutical Research Division, Ann Arbor, MI 48105, USA
J Lipid Res 36:823-38. 1995..These data indicate that ACAT mRNA14b levels increase in a tissue specific manner in response to dietary fat and cholesterol...